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Abstract. Time is an essential element in the clinical management
of patients as disease processes develop in time. Not surprisingly, the
amount of temporal clinical information that is being collected to un-
derstand what is happening in the patient is therefore continuously in-
creasing. A typical example of a disease process where time is considered
important is the development of ventilator-associated pneumonia (VAP)
during the stay in the ICU. A Bayesian network was developed previ-
ously to support clinicians in the diagnosis and treatment of VAP in
the ICU. In the research described in this paper, we have investigated
whether this Bayesian network can also be used to analyse the temporal
data collected in the ICU for patterns indicating development of VAP.
In addition, it was studied whether the Bayesian network was able to
suggest appropriate antimicrobial treatment. A temporal database with
over 17700 patient days was used for this purpose.
1 Introduction
Diagnosing disorders in critical care is a challenging task, as when a disorder is
missed and thus treatment is delayed this may actually be the cause of death of
a patient, as many of the patients in critical care are severely ill. Diagnosing a
disorder may also be difficult if there are few signs and symptoms that are typical
for the disorder, in particular if a disorder does not occur very frequently. This
is the situation with ventilator-associated pneumonia, or VAP for short. VAP is
a form of pneumonia that occurs in patients whom are mechanically ventilated
in critical care units and involves infection of the lower respiratory tract. This
has implications for the management of patients with VAP, as it is quite unlikely
that doctors are able to identify this low-prevalence disorder reliably, and they
may therefore need some form of decision support. As diagnosing a disorder in
medicine involves reasoning with uncertainty, we used a Bayesian network as our
primary tool for building a decision-support system. The development of VAP
is a time-based process, involving colonisation of the patient by microorganisms.
As diagnosing and monitoring a patient in critical care is a dynamic process
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Fig. 1. Bayesian network for Ventilator-Associated Pneumonia.
involvinf uncertainty, we will analyse clinical time series for patients who were
admitted to the ICU using a Bayesian network.
2 Bayesian networks in Biomedicine
Health care institutions collect large amounts of information about patients’
state and interventions taken by physicians and nursing staff, such as therapies.
The practical use of these ‘rough’ process data is still limited, since they are
not collected in controlled clinical trials [1]. However, the interest has grown to
analyse these data collections for management purposes. For understanding the
complex decision-making processes in health-care it is important to reason about
them. Since these processes often include uncertainty, Bayesian-network models
are constructed to support decision-making in real-life practice as a Bayesian
network is an excellent tool for reasoning with uncertainty [4].
Formally, a Bayesian network B = (G,Pr) is a directed acyclic graph G =
(V (G), A(G)) with set of vertices V (G) = {V1, . . . , Vn}, representing stochas-
tic variables, and a set of arcs A(G) ⊆ V (G) × V (G), representing statistical
dependences and independences among the variables. On the set of stochastic
Table 1. Data description including mean values.
Diagnosis VAP no VAP
n = 157 n = 17553
temperature 38.7 ◦C 37.9 ◦C
mech. ventilation 271h = 11.3d 268h ≈ 11.2d
leukocytes 13.8 13.0
pO2/FiO2 187 244
sputum 22.7 13.0
sputum pur. 74% 35%
culture positive negative
antipyr. drugs 82% 61%
x-chest positive negative
variables, a joint probability distribution Pr(V1, . . . , Vn) is defined that is fac-
torised respecting the (in)dependences represented in the graph:
Pr(V1, . . . , Vn)
n∏
i=1
Pr(Vi | pi(Vi))
where pi(Vi) stands for the variables corresponding to the parents of vertex Vi.
3 Patient Data
We had a temporal database of 17710 records at our disposal, each record repre-
senting data of a patient in the ICU during a period of 24 hours. The database
concerned 2233 distinct patients, who were all together 2424 times admitted to
the ICU. Thus, multiple admissions for one patient occurred. For 157 of the
17710 episodes, ventilator-associated pneumonia (VAP) was diagnosed by two
infectious-disease specialists (See Table 1 for a description of the patients’ data).
There is not a real gold standard for diagnosing ventilator-associated pneu-
monia. Important entities that are related to the development of VAP include
body temperature, drugs to suppress fever, amount of sputum, signs on the chest
X-ray, the ratio between the amount of oxygen in the arterial blood and the frac-
tional inspired oxygen concentration, i.e. pO2/FiO2, the duration of mechanical
ventilation, too few or too many leukocytes (white blood cells) and a sputum
culture [5]. These symptoms involve the diagnostic part of the Bayesian network
for VAP.
ICU patients become colonised by bacteria present in the ICU environment.
When colonisation of the lower respiratory tract occurs within 2–4 days after
intubation, this is usually caused by antibiotic-sensitive bacteria. When a VAP
is developed after 4 days of intubation, often antibiotic-resistant bacteria are
involved, which are more difficult to destroy. Therefore, it is important to start
treatment as soon as possible when an infection is suspected [2].
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Fig. 2. Timeline for patient 2.
It has been stated that the duration of hospital stay and the severity of illness
of a patient are associated with the prevalence of Gram-negative bacteria. We
modelled the bacteria species each as one vertex in the Bayesian network (See
Fig. 1). Also, for each modelled microorganism, the pathogenity, i.e. the influence
of the microorganism on the development of VAP, was included in the model.
The presence of certain bacteria has influence on the antimicrobial therapy. Each
microorganism is susceptible to some particular antibiotics. Susceptibility, in this
case, is stated as the sensitivity to or degree to which a microorganism is injured
by treatment with a specific antibiotic. The susceptibility of each microorgan-
ism was taken into account while constructing the model. Our infectious-disease
experts assigned utilities to each combination of microorganism(s) and antimi-
crobial drug(s) using a decision-theoretic model and estimated all conditional
probabilities [3]. These variables belong to the therapeutic part of the Bayesian
network for VAP.
4 The Role of Time in the Colonisation Process
The development of ventilator-associated pneumonia is a time-based process.
By including the variable mechanical ventilation in the Bayesian network, we
modelled the influence of time. Also, the node ‘hospitalisation’ represents a cer-
tain notion of time. The first 48 hours a patient is mechanically ventilated, the
probability of colonisation is low. After a period of two days, this probability is
higher and as a result, the probability of developing a VAP is also higher. Our
database represents the situation for several patients from admission to dismis-
sion. It would not be very usefull to look at the daily data individually, since a
physician does not work in this way either.
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Fig. 3. Timeline for patient 3.
We consider the period from admission to dismission of the patient as a time
series 〈Xt〉, t = 0, . . . , np, where t = np is the time of dismission of patient p.
For each record, we collected the output of the Bayesian network, i.e., the best
possible antimicrobial treatment. This antimicrobial treatment is based on the
utility, i.e. the preference - according to the experts, and the overall-susceptibility
of the microorganisms, i.e. the coverage. The optimal coverage is computed by
varying the therapy choise, and selecting the therapies with maximum expected
utility. Prescribing antibiotics is a trade-off between maximising coverage and
minimising broadness of spectrum. When a patient is known to be colonised with
a particular microorganism, the antimicrobial spectrum should be as narrow as
possible.
We randomly selected 8 patients with VAP. During the period of seven days
from timepoint of diagnosis, the patient is treated with antibiotics.
For each of the 8 patients, a timeline was drawn which shows colonisation
information and the period from the timepoint a VAP was concerned. As men-
tioned before, it is not clinically relevant to look at the data of one particilar
patient day. To judge a patient’s condition, we have to look at the data of more
than one day, thus we considered the time window [t, t+ 7], also taking into ac-
count information about (previous) colonisation, since this has direct influence
on the antimicrobial therapy. We took the minimal set of advised antibiotics
as the Bayesian network’s output. This advice was compared to actually pre-
scribed antibiotics, and agreement of disagreement between the two was judged
two infectious disease specialists.
For patients 2 and 3, the colonisation process is shown by a timeline in Fig.
2 and 3. The present microorganisms are depicted. The therapy advice of the
Bayesian network and the antibiotic treatment that was prescribed are presented
for each patient, together with the judgement of the infectious-disease experts,
in Table 2.
Table 2. Bayesian network versus infectious-disease specialists.
Patient Physician Bayesian Network Judgement
1 cefpirom meropenem spectrum much too broad
2 cefpirom clindamycin+aztreonam not the same, but correct
3 augmentin, ceftriaxon meropenem spectrum too broad
4 cefpirom meropenem not the same, but correct
5 augmentin meropenem spectrum much too broad
6 pipcil, ciproxin clindamycin+ciprofloxacin not the same, but correct
7 tazocin ceftriaxone not the same, but correct
8 ceftriaxon cotrimoxazol not the same, but correct
5 Conclusions and Future Work
Since the development of ventilator-associated pneumonia is a time-based pro-
cesses involving uncertainty, we have analysed temporal patient data using a
Bayesian network. In this paper, we have only analysed time-series data of 8
patient with VAP. One of the most important processes in VAP is the coloni-
sation by microorganisms. The results show that for 3 of the 8 patients, the
antibiotic spectrum was too broad. We noticed that the patients for whom a
correct therapy advice was given by the Bayesian network, were colonised by P.
aeruginosa.
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